Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q3 2022 · 10-Q
Revenue$93.00K$93.00K+8.1% vs Q3 2021 Net Income-$8.57M-$8.57MN/M vs Q3 2021 EPS Diluted-$0.20-$0.20N/M vs Q3 2021 Operating Income-$8,993,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,934,000N/M Margins · derivedOperating margin-9669.9%−1532.7 pt vs Q3 2021
Net margin-9216.1%−1177.8 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 3, 2022 · 34 d after period end